3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
71
Phase 3
60
Phase NA
36
Phase 1
17
Phase 1/2
9
Phase EARLY_PHASE1
2
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Hodgkin Disease
2
Breast Neoplasms
2
Anemia
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Radiotherapy
×
Clear all
NCT03948568
2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4
Completed
262 enrolled
NCT00742222
2016-05-17
EXIBT
Xoft, Inc.
Phase 4
Completed
63 enrolled